These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 3306667)
1. High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings. Safi F; Roscher R; Bittner R; Schenkluhn B; Dopfer HP; Beger HG Pancreas; 1987; 2(4):398-403. PubMed ID: 3306667 [TBL] [Abstract][Full Text] [Related]
2. CA 19-9 and pancreatic adenocarcinoma. Safi F; Beger HG; Bittner R; Büchler M; Krautzberger W Cancer; 1986 Feb; 57(4):779-83. PubMed ID: 3455839 [TBL] [Abstract][Full Text] [Related]
3. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9. Safi F; Roscher R; Beger HG Hepatogastroenterology; 1989 Dec; 36(6):419-23. PubMed ID: 2613165 [TBL] [Abstract][Full Text] [Related]
4. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer]. Safi F; Büchler M; Schenkluhn B; Beger HG Dtsch Med Wochenschr; 1984 Dec; 109(49):1869-73. PubMed ID: 6209082 [TBL] [Abstract][Full Text] [Related]
5. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma. Safi F; Roscher R; Beger HG Bull Cancer; 1990; 77(1):83-91. PubMed ID: 2180502 [TBL] [Abstract][Full Text] [Related]
6. CA 242 is a new tumor marker for pancreatic cancer. Röthlin MA; Joller H; Largiadèr F Cancer; 1993 Feb; 71(3):701-7. PubMed ID: 8431849 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical study of neuron-specific enolase and CA 19-9 in pancreatic disorders. The value of neuron-specific enolase as a marker for islet cell and nerve tissue. Iwase K; Kato K; Nagasaka A; Miura K; Kawase K; Miyakawa S; Tei T; Ohtani S; Inagaki M; Shinoda S Gastroenterology; 1986 Sep; 91(3):576-80. PubMed ID: 3015709 [TBL] [Abstract][Full Text] [Related]
8. [Ca 19-9 antigen in differentiation of pancreatic inflammatory and neoplastic tumors]. Markocka-Maczka K Wiad Lek; 2003; 56(11-12):537-40. PubMed ID: 15058160 [TBL] [Abstract][Full Text] [Related]
9. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Malesci A; Tommasini MA; Bonato C; Bocchia P; Bersani M; Zerbi A; Beretta E; Di Carlo V Gastroenterology; 1987 Jan; 92(1):60-7. PubMed ID: 3465666 [TBL] [Abstract][Full Text] [Related]
10. Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9. Haglund C; Lindgren J; Roberts PJ; Kuusela P; Nordling S Br J Cancer; 1989 Dec; 60(6):845-51. PubMed ID: 2557879 [TBL] [Abstract][Full Text] [Related]
11. Comparative study on the expression of the blood group antigens Le a, Le b, Le x, Le y and the carbohydrate antigens CA 19-9 and CA-50 in chronic pancreatitis and pancreatic carcinoma. Schwenk J; Makovitzky J Virchows Arch A Pathol Anat Histopathol; 1989; 414(6):465-76. PubMed ID: 2499104 [TBL] [Abstract][Full Text] [Related]
12. DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease. Mahvi DM; Seigler HF; Meyers WC; Kalthoff H; Schmiegel WH; Metzgar RS Pancreas; 1988; 3(4):488-93. PubMed ID: 3174610 [TBL] [Abstract][Full Text] [Related]
13. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma. Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259 [TBL] [Abstract][Full Text] [Related]
14. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease. Blind PJ; Dahlgren ST Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420 [TBL] [Abstract][Full Text] [Related]
15. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9. Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777 [TBL] [Abstract][Full Text] [Related]
16. The distribution and localization of the monoclonal antibody-defined antigen 19-9 (CA19-9) in chronic pancreatitis and pancreatic carcinoma. An immunohistochemical study. Makovitzky J Virchows Arch B Cell Pathol Incl Mol Pathol; 1986; 51(6):535-44. PubMed ID: 2878526 [TBL] [Abstract][Full Text] [Related]
17. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma. Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096 [TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma. Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775 [TBL] [Abstract][Full Text] [Related]
19. [Value of plasma testosterone, carcinoembryonic antigen and CA 19-9 in the differential diagnosis of pancreatic carcinoma and chronic pancreatitis]. Jurkowska G; Kulpa J; Skrodzka D; Rogowski F Pol Arch Med Wewn; 1992 Nov; 88(5):302-9. PubMed ID: 1300550 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of carbohydrate antigens 19-9 and 12-5 in patients with pancreatic cancer. Pasquali C; Sperti C; D'Andrea AA; Bonadimani B; Del Favero G; Petrin P; Pedrazzoli S Pancreas; 1987; 2(1):34-7. PubMed ID: 3472197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]